Clinical orthopedics encompasses a broad spectrum of conditions, from degenerative joint disease to complex musculoskeletal injuries. While interest in regenerative treatment options continues to grow, most current therapies remain focused on symptom management rather than true tissue repair.
Existing regenerative approaches—including mesenchymal stem cells (MSCs), platelet-rich plasma (PRP), and peptide-based treatments—have demonstrated variable clinical outcomes, and none have consistently shown durable structural regeneration or long-term disease modification.
Small Mobile Stem (SMS) cells represent a first-in-class, complex regenerative therapy. Due to their ultra-small size (4–6 μm), motility, and resilience, SMS cells can be delivered via direct intra-articular injection, enabling a multi-target therapeutic effect within joint tissues. SMS cells preferentially bind to cartilage repair cells, guide cellular differentiation and proliferation, modulate immune pathways, address vascular and neuronal pathology, and inhibit fibrosis—providing a broad-spectrum approach to joint preservation.
This publication reflects SMSbiotech’s ongoing platform development strategy and the evaluation of SMS cells across multiple therapeutic areas with significant unmet medical need.
To view the full article, please click Download White Paper in the Resources section below.
